| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b908fafd0da669294fc891fa3a6b0f7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 |
| filingDate |
2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f8bb5d0d8a0d3ecc7515b9f89650b98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0fad2d923ff05ab6c1e319385b10b12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4ecd15212621f4ca3d43671dbc5c55d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ecbfd926a033a592c09c029d4d211b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48f134a37a6aa8a4f7d50cc6f17d869b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1956fc1ec171247389b6c6460e6d976a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bb0adbea002b1cb51da63418c964100
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f228e88cde967e12265b33172b175614
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d86fba91ae78fbdbe6f4d845484886b |
| publicationDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109790170-A |
| titleOfInvention |
GABA(A) receptor modulators and methods of controlling airway hyperresponsiveness and inflammation in asthma |
| abstract |
Pyrrolobenzodiazepines target α-4 and α-5 GABA A receptors for the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds partition selectively to peripheral compartments and have reduced CNS effects. |
| priorityDate |
2016-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |